Antibody that binds human eosinophil-derived basic protein
US7932363B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Sep 7, 2005 |
| Grant date | Apr 26, 2011 |
| Priority date | — |
| Expiry date | Jul 26, 2029 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/851
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBPH and a method for producing EBPH. The invention also provides for use of EBPH and agonists, antibodies or antagonists specifically binding EBPH, in the prevention and treatment of diseases associated with expression of EBPH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding EBPH for the treatment of diseases associated with the expression of EBPH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding EBPH.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.